Date: 12-08-2026

National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex,
Bandra East, Mumbai-400051
Scrip Code: MUKKA

BSE Limited
Listing Department
Dalal Street,
Mumbai-400001
Scrip Code: 544135

Dear Sir/Madam,

Subject: Outcome of the Board Meeting held on 12th August 2026.

Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (including any statutory modification(s), amendment(s) or re-enactment(s) thereof for the time being in force), this is to inform you that the Board of Directors of the Company ("Board) at their meeting held today i.e. Wednesday, 12th August 2026, have *inter-alia* considered and approved the following business:

1. **Financial Results:** The unaudited financial results (standalone and consolidated) of the Company for the quarter and three months period ended 30th June 2026. The same is enclosed. Further, the Limited Review Report received from the Statutory Auditors of the Company is also enclosed.

2. **The 16th Annual General Meeting (AGM)** of the Company will be held on Thursday, 10th September 2026 at 3:00 p.m. through Video Conferencing/Other Audio-Visual Means ("VC/OAVM") facility.

3. **Cancellation and withdrawal of the proposed issuance of Non-Convertible Debentures on Private Placement Basis**
   The Board has approved the cancellation and withdrawal of the proposed issuance of Senior, Secured, Rated, Listed, Redeemable, Taxable, Transferable, INR Denominated Non-Convertible Debentures aggregating up to ₹75,00,00,000/- (Rupees Seventy-Five Crore Only) on a private placement basis.

4. **To invest in Swachha Eco Solutions Private Limited (SESPL)**: The Board has approved to make investment in SESPL and to make a capital contribution of **Rs. 64,92,500/- (Rupees Sixty-Four Lakh Ninety-Two Thousand Five Hundred Only)** representing 25.98% of the capital, thereby making SESPL an associate of the Company.

5. **Re-appointment of Mr. Karkala Shankar Balachandra Rao (DIN: 03589394) as a Non-Executive Independent Director of the Company:** Based on the recommendation of the Nomination and Remuneration Committee, the Board has approved the re-appointment of Mr. Karkala Shankar Balachandra Rao (DIN: 03589394) as a Non-Executive Independent Director of the Company for a second term of five (5) consecutive years, commencing from 15th January

2027 to 14th January 2032 (both days inclusive), subject to the approval of the Shareholders by way of a Special Resolution.

6. **Re-appointment of Mr. Hamad Bava (DIN: 09448423) as a Non-Executive Independent Director of the Company:** Based on the recommendation of the Nomination and Remuneration Committee, the Board has approved the re-appointment of Mr. Hamad Bava (DIN: 09448423) as a Non-Executive Independent Director of the Company for a second term of five (5) consecutive years, commencing from 15th January 2027 to 14th January 2032 (both days inclusive), subject to the approval of the Shareholders by way of a Special Resolution.

7. **Re-appointment of Mr. Narendra Surendra Kamath (DIN: 07255904) as a Non-Executive Independent Director of the Company:** Based on the recommendation of the Nomination and Remuneration Committee, the Board has approved the re-appointment of Mr. Narendra Surendra Kamath (DIN: 07255904) as a Non-Executive Independent Director of the Company for a second term of five (5) consecutive years, commencing from 15th January 2027 to 14th January 2032 (both days inclusive), subject to the approval of the Shareholders by way of a Special Resolution.

8. **Re-appointment of Mr. Kalandan Mohammed Haris (DIN: 03020471) as Managing Director and Chief Executive Officer of the Company**: Based on the recommendation of the Nomination and Remuneration Committee, the Board has approved the re-appointment of Mr. Kalandan Mohammed Haris (DIN: 03020471) as Managing Director and Chief Executive Officer of the Company for a further period of five (5) years, commencing from 20th January 2027 to 19th January 2032 (both days inclusive), subject to the approval of the Shareholders by way of a Special Resolution.

9. **Re-appointment of Mr. Kalandan Mohammed Althaf (DIN:03051103) as Whole-Time Director and Chief Financial Officer of the Company:** Based on the recommendation of the Nomination and Remuneration Committee ("NRC"), the Board has approved the re-appointment of Mr. Kalandan Mohammed Althaf (DIN:03051103) as Whole-Time Director and Chief Financial Officer of the Company for a further period of five (5) years, commencing from 20th January 2027 to 19th January 2032 (both days inclusive), subject to the approval of the Shareholders by way of a Special Resolution.

10. **To recommend the re-appointment of Mr. Kalandan Mohammad Arif (DIN:03020564) as Whole-Time Director and Chief Operating Officer of the Company:** Based on the recommendation of the Nomination and Remuneration Committee, the Board has approved the re-appointment of Mr. Kalandan Mohammad Arif (DIN:03020564) as Whole-Time Director and Chief Operating Officer of the Company for a further period of five (5) years, commencing from 20th January 2027 to 19th January 2032 (both days inclusive), subject to the approval of the Shareholders by way of a Special Resolution.

The detailed disclosure as required under SEBI Circular No. SEBI/HO/CFD/CFDPoD1/P/CIR/2023/123 dated July 13, 2023 and such other circulars as applicable, in respect of Sl. No. 4 to 10 is enclosed as Annexure I to III.

Factory : D. No. 14-161 to 164, Sasihithlu Road, Mukka, Mangaluru - 575021. Karnataka, India
Office : Mukka Corporate House, Door No. 18-2-16/4, First Cross, NG Road, Attavara, Mangaluru, Dakshina Kannada, Karnataka, India - 575001
: (O) +91 824 2420772, 2442889, 4252889 | Fax : +91 824 2426405
E-mail : info@mukkaproteins.com - Website : www.mukkaproteins.com - CIN : L10207KA2010PLC055771

The Meeting commenced at 03:30 p.m. and concluded at 4:15 p.m.

This is for your information and records.

Thank you,
For **Mukka Proteins Limited**

MEHABOOBSAB MAHMADGOUS CHALYAL
Digitally signed by MEHABOOBSAB MAHMADGOUS CHALYAL
Date: 2026.08.12 16:24:14 +05'30'

Mehaboobsab Mahmadgous Chalyal
Company Secretary & Compliance Officer
Membership No.: A67502

Encl: as above.

Factory : D. No. 14-161 to 164, Sasihithlu Road, Mukka, Mangaluru - 575021. Karnataka, India
Office : Mukka Corporate House, Door No. 18-2-16/4, First Cross, NG Road, Attavara, Mangaluru, Dakshina Kannada, Karnataka, India - 575001
: (0) +91 824 2420772, 2442889, 4252889 | Fax : +91 824 2426405
E-mail : info@mukkaproteins.com - Website : www.mukkaproteins.com - CIN : L10207KA2010PLC055771

SHAH & TAPARIA
CHARTERED ACCOUNTANTS

203, Center Point Building, 100, Dr. Babasaheb Ambedkar Road,
Opp. Bharatmata Theater, Lalbaug, Parel, Mumbai - 400 012.
Tel.: 022 - 42116800 Fax : 022-4022 0314
E-mail : Info@shahtaparia.com
Visit us at : www.shahtaparia.com

Independent Auditor's Review Report on Quarterly and Year to Date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
The Board of Directors
Mukka Proteins Limited

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **Mukka Proteins Limited** ("the Parent"), its subsidiaries (the Parent and its subsidiaries together referred to as "**the Group**") and Group's share of the net profit/loss after tax and total comprehensive income/loss of its joint ventures, for the quarter ended June 30, 2026 ('the Statement') attached herein, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the Circular No. CIR/CFD/CMDI/44/2019 dated March 29, 2019 issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

SHAH & TAPARIA
Reg. No. 109463W
203, Centre Point Bldg.,
100, Dr. Ambedkar Road,
Opp. Bharat Mata Cinema,
Lalbaug, Parel,
Mumbai-400 012.
CHARTERED ACCOUNTANTS

SHAH & TAPARIA
CHARTERED ACCOUNTANTS

203, Center Point Building, 100, Dr. Babasaheb Ambedkar Road,
Opp. Bharatmata Theater, Lalbaug, Parel, Mumbai - 400 012.
Tel.: 022 - 42116800 Fax : 022-4022 0314
E-mail : Info@shahtaparia.com
Visit us at : www.shahtaparia.com

4. The Statement includes the results of the following entities:

Name of the Entity	**Relationship**
Mukka Proteins Limited	Parent Company
Haris Marine Products Private Limited	Wholly Owned Subsidiary Company (Domestic)
Atlantic Marine Products Private Limited	Subsidiary Company (Domestic)
Ocean Aquatic Proteins LLC	Subsidiary Company (Foreign)
Ento Proteins Private Limited	Wholly Owned Subsidiary Company (Domestic)
Fabbco Bio Cycle and Bio Protein Technology Private Limited	Subsidiary Company (Domestic)
Ocean Proteins Private Limited	Subsidiary Company (Domestic)
United Gulf Fishery Products LLC	Subsidiary Company (Foreign)
Mukka Frozen Impex	Subsidiary Entity (Domestic)
MPL HRC Eco Solution LLP	Subsidiary Entity (Domestic)
Delta Marine Products	Subsidiary Entity (Domestic)
Ullal Fish Meal and Oil Company	Joint Venture
GSM Marine Export	Joint Venture
Progress Frozen and Fish Sterilization	Joint Venture
Pacific Marine Products	Joint Venture
Mangalore Fishmeal and Oil Company	Joint Venture – Indirect

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the

SHAH & TAPARIA
Reg. No. 109463W
203, Centre Point Bldg., 100, Dr. Ambedkar Road, Opp. Bharat Mata Cinema, Lalbaug, Parel, Mumbai-400 012.
CHARTERED ACCOUNTANTS

203, Center Point Building, 100, Dr. Babasaheb Ambedkar Road,
Opp. Bharatmata Theater, Lalbaug, Parel, Mumbai - 400 012.
Tel.: 022 - 42116800 Fax : 022-4022 0314
E-mail : Info@shahtaparia.com
Visit us at : www.shahtaparia.com

SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the interim financial information/ financial results of ten subsidiaries included in the Statement, whose interim financial information/ financial results reflect total revenues of Rs. 1511.47 million for the quarter ended June 30, 2026, total net loss after tax of Rs. 7.81 million for the quarter ended June 30, 2026 and total comprehensive loss of Rs. 12.15 million for the quarter ended June 30, 2026 as considered in the Statement which have been reviewed by other auditors, whose reports has been furnished to us by the Company's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

   Further, we did not review the interim financial information/ financial results of Five Joint Ventures included in the Statement, whose interim financial information/ financial results reflect share of loss amounting to Rs. 9.51 million for the quarter ended June 30, 2026, Total Comprehensive Loss amounting to Rs. 9.51 million for the quarter ended June 30, 2026 as considered in the statement which have been reviewed by other auditors, whose reports have been furnished to us by the Company's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

   Our conclusion on the Statement is not modified in respect of this matter.

For SHAH & TAPARIA
Chartered Accountants
FRN: 109463W

SHAH & TAPARIA
Reg. No. 109463W
203, Centre Point Bldg.,
100, Dr. Ambedkar Road,
Opp. Bharat Mata Cinema,
Lalbaug, Parel,
Mumbai-400 012.
CHARTERED ACCOUNTANTS

Bharat Joshi
Partner
M. No.: 130863
UDIN: 26130863QOSKAQ4763
Date: August 12, 2026
Place: Mumbai

MUKKA PROTEINS LIMITED
CIN: L10207KA2010PLC055771
STATEMENT OF UN-AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026

(Rupees in million, except per share data and if otherwise stated)

Sr. No.	Particulars	Quarter Ended			Year Ended
		June 30, 2026	March 31,2026	June 30, 2025	March 31, 2026
		(Un-Audited)	(Audited)	(Un-Audited)	(Audited)
1	**Revenue from Operations**				
	Revenue from operations	4,748.04	3,679.16	1,648.81	14,035.15
	Other operating income	148.50	126.85	58.92	459.38
	Total Revenue from operations	**4,896.54**	**3,806.01**	**1,707.74**	**14,494.53**
2	Other income	15.92	151.94	25.55	286.81
3	**Total income**	**4,912.47**	**3,957.95**	**1,733.28**	**14,781.35**
4	**Expenses**				
	Cost of Material Consumed	3,919.82	3,754.59	1,928.46	14,307.25
	Changes in inventories of finished goods, stock in trade and work in progress	(101.27)	(750.83)	(635.21)	(2613.95)
	Employee benefits expenses	163.35	131.30	78.89	407.75
	Finance costs	164.52	151.70	110.41	535.96
	Depreciation and amortisation	47.97	51.25	32.62	165.92
	Other expenses	434.84	332.36	190.05	1,247.67
	Total expenses	**4,629.22**	**3,670.36**	**1,705.22**	**14,050.60**
5	**Profit before exceptional item, Share of Net Profit / (loss) of Associates and Joint Ventures and tax (3-4)**	**283.25**	**287.60**	**28.06**	**730.75**
6	**Exceptional items**	-	-	-	-
7	**Share of Net Profit / (loss) of Associates and Joint Ventures**	(9.51)	1.27	(4.47)	20.69
8	**Profit before tax (5-6+7)**	**273.74**	**288.87**	**23.59**	**751.44**
9	**Total tax expenses**				
	Current Tax	61.92	85.70	8.04	189.82
	Deferred Tax	25.48	(19.30)	(0.34)	(17.92)
	Earlier years	-	8.88	-	8.67
10	**Profit after tax (8-9)**	**186.34**	**213.59**	**15.89**	**570.86**
11	**Other Comprehensive Income**				
	Items that will not be reclassified subsequently to profit or loss				
	Remeasurement of the net defined benefit plans	**5.29**	**2.08**	**0.21**	**5.19**
	Items that will be reclassified subsequently to profit or loss				
	Exchange differences on translation of foreign operations	4.92	(10.76)	(0.74)	(11.31)
	Total other comprehensive income	**10.21**	**(8.67)**	**(0.53)**	**(6.12)**
12	**Total comprehensive income (10+11)**	**196.55**	**204.91**	**15.36**	**564.73**
	Profit for the year attributable to:				
	Shareholders of the Company	188.88	206.15	15.17	520.58
	Non-controlling interests	(2.53)	7.44	0.72	50.28
	Other comprehensive income for the year attributable to:				
	Shareholders of the Company	8.16	(4.69)	(0.25)	(1.94)
	Non-controlling interests	2.04	(3.98)	(0.27)	(4.19)
13	**Paid-up equity share capital (Face Value of the share Re. 1/- each) ***	300.00	300.00	300.00	300.00
14	Other equity	-	-	-	4,690.86
15	**Earnings per share * (Face Value Rs. 1 /- per share)**				
	(a) Basic	0.63	0.69	0.05	1.74
	(b) Diluted	0.63	0.69	0.05	1.74

*** Basic & Diluted EPS for all periods , except year ended March 31, 2026 , are not annualised.*
See accompanying notes to the financial results

MUKKA PROTEINS LIMITED Mangaluru

MUKKA PROTEINS LIMITED
CIN: L10207KA2010PLC055771
NOTES TO THE STATEMENT OF UN-AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026

1 The above statement of Un-Audited consolidated financial results for the Quarter & Period Ended June30, 2026 ('the Statement') of Mukka Proteins Limited ('the Company') are reviewed and recommended by the Audit Committee and taken on record by the Board of Directors at their meeting held on **August 12, 2026**. The Statutory auditors have carried out an review of the consolidated financial results for the Quarter & Period Ended June 30,2026.

2 The Un-Audited Consolidated Financial Results of the company are prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with the Companies (Indian Accounting Standard Rules), 2015 (as amended) and in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015, as amended.

3 The figures for the quarter ended March 31, 2026 are balancing figure between the audited figures for the year ended March 31, 2026 and published year to date figures for nine months ended December 31, 2025.

4 The Group operates in a single operating segment namely Fish & Insects Protein. The Board of directors is the Chief Operating Decision Maker (the "CODM") of the group and makes operating decisions, assess financials performance & allocate resources based upon discrete financial information. Since the Company operate in a single operating segment, separate segment reporting has not been made under Indian Accounting Standard ("Ind AS") 108 - "Operating Segment". Further, the operation of the Group comprises of geographical segment as disclosed below -

Revenue disaggregation by geography is as follows :-

(Rupees in Million)

Particulars	Quarter Ended			Year Ended
	June 30, 2026	March 31,2026	June 30, 2025	March 31, 2026
	(Un-Audited)	(Audited)	(Un-Audited)	(Audited)
Within India	607.36	340.86	120.10	2,853.77
Outside India	4,140.68	3,338.30	1,528.72	11,181.38
Total	**4,748.04**	**3,679.16**	**1,648.81**	**14,035.15**

5 The figures for comparative period have been regrouped/ reclassified, wherever necessary, to make them comparable.

For and on behalf of Board of Directors of Mukka Proteins Limited

MUKKA PROTEINS LIMITED Mangaluru

Kalandan Mohammed Haris
Managing Director and CEO
DIN: 03020471

Date - August 12, 2026
Place: Mangalore

SHAH & TAPARIA
CHARTERED ACCOUNTANTS

203, Center Point Building, 100, Dr. Babasaheb Ambedkar Road,
Opp. Bharatmata Theater, Lalbaug, Parel, Mumbai - 400 012.
Tel.: 022 - 42116800 Fax : 022-4022 0314
E-mail : Info@shahtaparia.com
Visit us at : www.shahtaparia.com

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
The Board of Directors,
Mukka Proteins Limited

1. We have reviewed the accompanying statement of unaudited Standalone Financial Results of **Mukka Proteins Limited** ('the Company'), for the quarter ended 30th June 2026, (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 and other applicable regulations of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations") including relevant circulars issued by SEBI from time to time.

2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" (`Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the statement has not been prepared in all material

SHAH & TAPARIA
Reg. No.109463W
203, Centre Point Bldg.,
100, Dr. Ambedkar Road,
Opp. Bharat Mata Cinema,
Lalbaug, Parel,
Mumbai-400 012.
CHARTERED ACCOUNTANTS

203, Center Point Building, 100, Dr. Babasaheb Ambedkar Road,
Opp. Bharatmata Theater, Lalbaug, Parel, Mumbai - 400 012.
Tel.: 022 - 42116800 Fax : 022-4022 0314
E-mail : Info@shahtaparia.com
Visit us at : www.shahtaparia.com

respects in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For SHAH & TAPARIA
Chartered Accountants
FRN: 109463W

Bharat Joshi
Partner
M. No.: 130863
UDIN: 26130863RYDMEB8850

Date: August 12, 2026
Place: Mumbai

MUKKA PROTEINS LIMITED
CIN: L10207KA2010PLC055771
STATEMENT OF UN-AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026

(Rupees in million, except per share data and if otherwise stated)

Sr. No.	Particulars	Quarter Ended			Year ended
		June 30,2026	March 31, 2026	June 30,2025	March 31, 2026
		(Un-Audited)	(Audited)	(Un-Audited)	(Audited)
1	**Revenue from operations**				
	Revenue from operations	3,927.05	3,002.56	1,299.00	11,849.54
	Other operating income	131.51	126.21	58.92	442.51
	Total Revenue from operations	**4,058.56**	**3,128.77**	**1,357.92**	**12,292.05**
2	Other income	22.99	137.93	28.43	292.68
3	**Total income (1+2)**	**4,081.55**	**3,266.70**	**1,386.35**	**12,584.73**
4	**Expenses**				
	Cost of Material Consumed	3,405.13	3,152.80	1,715.43	12,644.41
	Changes in inventories of finished goods, stock in trade and work in progress	(161.42)	(666.05)	(687.28)	(2535.76)
	Employee benefits expenses	62.92	62.41	50.95	245.13
	Finance costs	146.67	137.44	103.50	499.10
	Depreciation and amortisation expenses	19.69	25.60	13.56	69.39
	Other expenses	333.57	288.43	172.22	1,074.66
	Total expenses	**3,806.56**	**3,000.63**	**1,368.38**	**11,996.94**
5	**Profit before exceptional item and tax (3-4)**	**274.99**	**266.07**	**17.97**	**587.79**
6	**Exceptional items**	-	-	-	-
7	**Profit before tax (5-6)**	**274.99**	**266.07**	**17.97**	**587.79**
8	**Total tax expenses**				
	Current Tax	55.89	88.67	7.09	171.68
	Deferred Tax	25.02	(19.98)	0.00	(16.29)
	Earlier years	-	8.28	(0.47)	8.28
9	**Profit after tax (7-8)**	**194.07**	**189.09**	**11.35**	**424.12**
10	**Other Comprehensive Income/ (Expenses) (net of tax)**				
	Items that will not be reclassified to profit or loss				
	-Remeasurements of the defined benefit plans	5.29	2.08	0.21	5.19
	Other comprehensive income, net of tax	**5.29**	**2.08**	0.21	**5.19**
11	**Total Comprehensive Income for the Period (after tax) (9+10)**	**199.36**	**191.18**	**11.56**	**429.32**
12	**Paid-up equity share capital (Face Value of the share Rs. 1/- each)**	300.00	300.00	300.00	300.00
13	Other equity	-	-	-	4,172.98
14	**Earnings per share * (Face Value Rs. 1 /- per share)**				
	(a) Basic	0.66	0.64	0.04	1.43
	(b) Diluted	0.66	0.64	0.04	1.43

*** Basic & Diluted EPS for all periods , except year ended March 31, 2026 are not annualised.*
See accompanying notes to the financial results

MUKKA PROTEINS LIMITED
Mangaluru

MUKKA PROTEINS LIMITED
CIN: L10207KA2010PLC055771
NOTES TO THE STATEMENT OF UN- AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026

1 The above statement of Un-audited Standalone Financial Results for the Quarter & Period ended June 30, 2026 ('the Statement') of Mukka Proteins Limited ('the Company') are reviewed and recommended by the Audit Committee and taken on record by the Board of Directors at their meeting held on **August 12, 2026.** The Statutory auditors have carried out limited review of the standalone financial results for the Quarter ended June 30, 2026.

2 The Un-Audited Standalone Financial Results of the company are prepared in accordance with the Indian Accounting Standards (lnd AS) as prescribed under Section 133 of the Companies Act, 2013 read with the Companies (Indian Accounting Standard Rules), 2015 (as amended) and in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015, as amended.

3 The figures for the quarter ended March 31, 2026 are balancing figure between the audited figures for the year ended March 31, 2026 and published year to date figures for nine months ended December 31, 2025.

4 The Group operates in a single operating segment namely Fish & Insects Protein. The Board of directors is the Chief Operating Decision Maker (the "CODM") of the group and makes operating decisions, assess financials performance & allocate resources based upon discrete financial information. Since the Company operate in a single operating segment, separate segment reporting has not been made under Indian Accounting Standard ("Ind AS") 108 - "Operating Segment". Further, the operation of the Group comprises of geographical segment as disclosed below -

Revenue disaggregation by geography is as follows :-

(Rupees in Million)

Particulars	Quarter Ended			Year ended
	June 30, 2026	March 31,2026	June 30,2025	March 31, 2026
	(Audited)	(Audited)	(Un-Audited)	(Audited)
Within India	400.51	167.52	114.72	2,406.66
Outside India	3526.55	2835.05	1184.28	9,442.88
Total	**3,927.05**	**3,002.56**	**1,299.00**	**11,849.54**

5 The figures for comparative period have been regrouped/ reclassified, wherever necessary, to make them comparable.

For and on behalf of Board of Directors of
Mukka Proteins Limited

MUKKA PROTEINS LIMITED Mangaluru

Kalandan Mohammed Haris
Managing Director and CEO
DIN: 03020471

Date - August 12, 2026
Place: Mangalore

Annexure – I

S. No.	Particulars	Details
1.	Name of the target entity, details in brief such as size, turnover etc.;	Name of the Target entity: Swaccha Eco Solutions Private Limited ("SESPL") Authorized Capital: Rs. 10,00,000/- Paid up Capital: Rs. 5,00,000/- Turnover (FY 2025-26): Rs. 1,77,61,136/- PAT (FY 2025-26): Rs. (75,05,051) Net worth (FY 2025-26): Rs. (2,10,22,476)
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length";	Not a related party transaction.
3.	Industry to which the entity being acquired belongs;	Collection, treatment and disposal of all types of waste
4.	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	The proposed investment is being made as a part of Company's strategic investment plans to expand the Waste Management segment of the Company.
5.	Brief details of any governmental or regulatory approvals required for the acquisition;	Not Applicable
6.	Indicative time period for completion of the acquisition;	31-12-2026
7.	Consideration - whether cash consideration or share swap or any other form and details of the same;	Cash
8.	Cost of acquisition and/or the price at which the shares are acquired;	Acquisition of 26,500 equity shares of face value of Rs.10/- each of SESPL at a price of Rs. 250/- per equity share for a total consideration of Rs. 64,92,500/-.
9.	Percentage of shareholding / control acquired and / or number of shares acquired;	Proposed to acquire 26,500 equity shares of face value of Rs.10/- each of SESPL at a price of Rs. 250/- per equity share for a total consideration of Rs. 64,92,500/-. Post-acquisition Shareholding will be 25.98%.

Factory : D. No. 14-161 to 164, Sasihithlu Road, Mukka, Mangaluru - 575021. Karnataka, India
Office : Mukka Corporate House, Door No. 18-2-16/4, First Cross, NG Road, Attavara, Mangaluru, Dakshina Kannada, Karnataka, India - 575001
: (0) +91 824 2420772, 2442889, 4252889 | Fax : +91 824 2426405
E-mail : info@mukkaproteins.com - Website : www.mukkaproteins.com - CIN : L10207KA2010PLC055771

10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	SESPL is in the business of Collection, treatment and disposal of all types of waste. Line of Business: Collection, treatment and disposal of all types of waste Date of Incorporation: 12th September 2017 Turnover of last 3 years: As on March 2024: Rs. 1,44,45,028/- As on March 2025: Rs. 2,77,64,810/- As on March 2026: Rs. 1,77,61,136/- Country in which the acquired entity has presence: India

Factory : D. No. 14-161 to 164, Sasihithlu Road, Mukka, Mangaluru - 575021. Karnataka, India
Office : Mukka Corporate House, Door No. 18-2-16/4, First Cross, NG Road, Attavara, Mangaluru, Dakshina Kannada, Karnataka, India - 575001
: (O) +91 824 2420772, 2442889, 4252889 | Fax : +91 824 2426405
E-mail : info@mukkaproteins.com - Website : www.mukkaproteins.com - CIN : L10207KA2010PLC055771

Annexure -II

S. No.	Particulars	Details		
		Mr. Karkala Shankar Balachandra Rao	**Mr. Hamad Bava**	**Mr. Narendra Surendra Kamath**
1.	Reason for Change viz. ~~appointment~~, re-appointment, ~~resignation, removal, death or otherwise~~	The Board of Directors have at their meeting held today viz. Wednesday, 12th August 2026, on the basis of recommendation of the Nomination and Remuneration Committee, approved the re-appointment of Mr. Karkala Shankar Balachandra Rao (DIN: 03589394) as the Independent Director of the Company, not being liable to retire by rotation, for a 2nd term of five consecutive years commencing from 15th January 2027 to 14th January 2032 (both days inclusive), subject to approval of the shareholders of the Company at the ensuing 16th Annual General Meeting of the Company.	The Board of Directors have at their meeting held today viz. Wednesday, 12th August 2026, on the basis of recommendation of the Nomination and Remuneration Committee, approved the re-appointment of Mr. Hamad Bava (DIN: 09448423) as the Independent Director of the Company, not being liable to retire by rotation, for a 2nd term of five consecutive years commencing from 15th January 2027 to 14th January 2032 (both days inclusive), subject to approval of the shareholders of the Company at the ensuing 16th Annual General Meeting of the Company.	The Board of Directors have at their meeting held today viz. Wednesday, 12th August 2026, on the basis of recommendation of the Nomination and Remuneration Committee, approved the re-appointment of Mr. Narendra Surendra Kamath (DIN: 07255904) as the Independent Director of the Company, not being liable to retire by rotation, for a 2nd term of five consecutive years commencing from 15th January 2027 to 14th January 2032 (both days inclusive), subject to approval of the shareholders of the Company at the ensuing 16th Annual General Meeting of the Company.
2.	Date of ~~appointment~~ / re-appointment ~~/cessation (as applicable) & term of appointment / re-appointment~~	Date of re-appointment – w.e.f.15th January 2027 Term of Re-appointment – 2nd term of five consecutive years commencing from 15th January 2027 to 14th January 2032 (both days inclusive)	Date of re-appointment – w.e.f. 15th January 2027 Term of Re-appointment – 2nd term of five consecutive years commencing from 15th January 2027 to 14th January 2032 (both days inclusive)	Date of re-appointment – w.e.f. 15th January 2027 Term of Re-appointment – 2nd term of five consecutive years commencing from 15th January 2027 to 14th January 2032 (both days inclusive)
3.	Brief Profile	He has worked for Canara Bank in various capacities from 1973 to 2014. He was previously a Director of Canara Bank Securities	He was previously employed with Vijaya Bank from the year 1975 to 2012. He has over 35 (thirty-five) years of experience in banking sector.	He previously worked with Reliance Big Entertainment Private Limited as Vice President-Finance from May 28,

Factory : D. No. 14-161 to 164, Sasihithlu Road, Mukka, Mangaluru - 575021. Karnataka, India
Office : Mukka Corporate House, Door No. 18-2-16/4, First Cross, NG Road, Attavara, Mangaluru, Dakshina Kannada, Karnataka, India - 575001
: (O) +91 824 2420772, 2442889, 4252889 | Fax : +91 824 2426405
E-mail : info@mukkaproteins.com - Website : www.mukkaproteins.com - CIN : L10207KA2010PLC055771

		Limited from September 16, 2011 to March 31, 2014. He has over 40 years of experience in Banking, Credit, Foreign Exchange etc.	He has also served as Finance Manager at Yenepoya Institute of Medical Sciences and Research Private Limited, Mangaluru for a period of 7 years from year 2013 to 2019. He is a member of a Non-Governmental Organisation - Jamiyyatul Falah, Mangaluru Corporation Unit.	2019 to February 12, 2021. He has also served as a Director in Reliance Big Entertainment Private Limited, Reliance Entertainment Ventures Private Limited, Zapak Mobile Games Private Limited and Big Flicks Private Limited.
4.	Disclosure of relationship between Directors	Not Applicable	Not Applicable	Not Applicable
5.	Information as required pursuant to BSE Circular with ref. no. LIST/COMP/14/2018-19 and the National Stock Exchange of India Limited Circular with ref. no. NSE/CML/2018/ 24, both dated 20 June 2018	Mr. Karkala Balachandra Rao is not debarred from holding the office of director by virtue of any SEBI order or any other such authority.	Mr. Hamad Bava is not debarred from holding the office of director by virtue of any SEBI order or any other such authority.	Mr. Narendra Surendra Kamath is not debarred from holding the office of director by virtue of any SEBI order or any other such authority.

Factory : D. No. 14-161 to 164, Sasihithlu Road, Mukka, Mangaluru - 575021. Karnataka, India
Office : Mukka Corporate House, Door No. 18-2-16/4, First Cross, NG Road, Attavara, Mangaluru, Dakshina Kannada, Karnataka, India - 575001
: (O) +91 824 2420772, 2442889, 4252889 | Fax : +91 824 2426405
E-mail : info@mukkaproteins.com - Website : www.mukkaproteins.com - CIN : L10207KA2010PLC055771

Annexure – III

S. No.	Particulars	Details		
		Mr. Kalandan Mohammed Haris	**Mr. Kalandan Mohammed Althaf**	**Mr. Kalandan Mohammad Arif**
1.	Reason for Change viz. ~~appointment~~, re-appointment, ~~resignation, removal, death or otherwise~~	The Board of Directors have at their meeting held today viz. Wednesday, 12th August 2026, on the basis of recommendation of the Nomination and Remuneration Committee, approved the re-appointment of Mr. Kalandan Mohammed Haris (DIN: 03020471) as Managing Director and Chief Executive Officer of the Company, to hold office for a further period of 5 (Five) years with effect from 20th January 2027 to 19th January 2032 (both days inclusive) whose office as a Managing Director shall not be liable to retire by rotation in an annual general meeting subject to approval of the shareholders of the Company at the ensuing 16th Annual General Meeting of the Company.	The Board of Directors have at their meeting held today viz. Wednesday, 12th August 2026, on the basis of recommendation of the Nomination and Remuneration Committee, approved the re-appointment of Mr. Kalandan Mohammed Althaf (DIN:03051103) as Whole-Time Director and Chief Financial Officer of the Company, to hold office for a further period of 5 (Five) years with effect from 20th January 2027 to 19th January 2032 (both days inclusive) whose office as a Director shall be liable to retire by rotation subject to approval of the shareholders of the Company at the ensuing 16th Annual General Meeting of the Company.	The Board of Directors have at their meeting held today viz. Wednesday, 12th August 2026, on the basis of recommendation of the Nomination and Remuneration Committee, approved the re-appointment of Mr. Kalandan Mohammad Arif (DIN:03020564) as Whole-Time Director and Chief Operating Officer of the Company, to hold office for a further period of 5 (Five) years with effect from 20th January 2027 to 19th January 2032 (both days inclusive) whose office as a Director shall be liable to retire by rotation subject to approval of the shareholders of the Company at the ensuing 16th Annual General Meeting of the Company.
2.	Date of ~~appointment~~ / re-appointment ~~/cessation (as applicable) & term of appointment / re-appointment~~	Date of re-appointment – w.e.f. 20th January 2027 Term of Re-appointment – Five years commencing from 20th January 2027 to 19th January 2032 (both days inclusive)	Date of re-appointment – w.e.f. 20th January 2027 Term of Re-appointment – Five years commencing from 20th January 2027 to 19th January 2032 (both days inclusive)	Date of re-appointment – w.e.f. 20th January 2027 Term of Re-appointment – Five years commencing from 20th January 2027 to 19th January 2032 (both days inclusive)
3.	Brief Profile	He has around 25 years of experience in the fish meal manufacturing industry. He is responsible for the day-to-day management and business affairs of the	He has around 25 years of experience in the fish meal manufacturing industry. He has been actively involved in managing the Company's finances, including financial	He has around 15 years of experience in the fish meal manufacturing industry. He is responsible for overseeing the day-to-day plant operations of the

Factory : D. No. 14-161 to 164, Sasihithlu Road, Mukka, Mangaluru - 575021. Karnataka, India
Office : Mukka Corporate House, Door No. 18-2-16/4, First Cross, NG Road, Attavara, Mangaluru, Dakshina Kannada, Karnataka, India - 575001
: (0) +91 824 2420772, 2442889, 4252889 | Fax : +91 824 2426405
E-mail : info@mukkaproteins.com - Website : www.mukkaproteins.com - CIN : L10207KA2010PLC055771

		Company. He has been actively involved in developing and implementing the Company's business strategy and overseeing its operations.	reporting, budgeting, forecasting, and cash flow management and maintaining our banking relationships. He has also been actively involved in the international business development, sales, and marketing of the Company.	Company. He has been actively involved in managing our operations, including production, logistics, and quality control. He is also responsible for the strategic sourcing of fish and supply chain operations.
4.	Disclosure of relationship between Directors	• Son of Kalandan Abdul Razak & Umaiyya Banu • Brother of Kalandan Mohammed Althaf & Kalandan Mohammad Arif	• Son of Kalandan Abdul Razak & Umaiyya Banu • Brother of Kalandan Mohammed Haris & Kalandan Mohammad Arif	• Son of Kalandan Abdul Razak & Umaiyya Banu • Brother of Kalandan Mohammed Haris & Kalandan Mohammed Althaf
5.	Information as required pursuant to BSE Circular with ref. no. LIST/COMP/14/2018-19 and the National Stock Exchange of India Limited Circular with ref. no. NSE/CML/2018/ 24, both dated 20 June 2018	Mr. Kalandan Mohammed Haris is not debarred from holding the office of director by virtue of any SEBI order or any other such authority.	Mr. Kalandan Mohammed Althaf is not debarred from holding the office of director by virtue of any SEBI order or any other such authority.	Mr. Kalandan Mohammad Arif is not debarred from holding the office of director by virtue of any SEBI order or any other such authority.